Biomarkers identifi ed by -omics
Th e major problem is that RA is a heterogeneous disease, with disease course and extent of connective tissue destruction varying considerably among patients. Histological evaluation of the infl amed synovium confi rms the heterogeneity in RA, and cDNA microarray analysis of synovial tissue showed that, for example, STAT1 (signal tranducing and activator of transcription-1) gene expression distinguishes between RA subtypes [3] . For the diagnosis and management of disease, however, the genetic analysis of the infl amed synovial tissue is cumbersome. Blood is a highly dynamic environment, communicating with practically every tissue in the body, and is thus proposed as a 'sentinel tissue' that refl ects disease progression in the body. Blood not only transports soluble biomarkers but because the leukocytes interact and communicate with practically every tissue, they bear rich information regarding infl ammation and immune responses. Whole genome expression profi ling of blood cells from RA patients has identifi ed marker genes the expression of which predicts with 86% accuracy the response of infl iximab in RA [4] . More importantly, only eight marker genes are needed to evaluate blood cells for a valid prediction. Another study showed that the expression of CD11c is a biomarker in monocytes to identify responders to abdalumimab [5] . Interestingly, the correlation of CD11c with response was lost when methotrexate was co-administered, showing the narrow window of CD11c as a predictive transcriptional biomarker. Many other genes are signifi cantly upregulated in RA peripheral blood mononuclear cells compared to healthy controls -for example, those encoding CD14 antigen, defensin-a1/3, and S100A proteins, which are of potential diagnostic and prognostic value for RA. Over the past decade, proteomics have yielded potential new Abstract It has long been recognized that laboratory tests are useful in the diagnosis of disease and to monitor treatment outcome. Their performance has become even more demanding with the development of personalized medicine. In patients with rheumatoid arthritis (RA) the standard biochemical tests measure serological markers of disease, such as C-reactive protein, and RA-associated auto-antibodies, such as rheumatoid factor and anti-citrullinated protein antibodies. The information obtained from these markers does not, however, provide a complete picture of the disease and treatment effi cacy. New biomarkers based on cytokine receptor complexes are promising for RA theragnostics.
candidates in the quest for better biomarkers for RA, including the S100 proteins, serum amyloid A, alpha 1-antitrypsin, and apolipoproteins in the blood [6] . In principle, carbohydrates, lipids and proteins (including enzymes, matrix proteins or their neoepitopes, autoantibodies, acute-phase proteins, chemokines, growth factors, cytokines and their inhibitors, and receptors) can be biomarkers for infl ammation, connective tissue destruction, diagnosis and prognosis in RA (reviewed by Carrasco and Barton [7] ).
Soluble IL-18 receptor complex
Cytokines and cytokine-related molecules play a key role in the pathogenesis of RA. Levels of TNFα, the soluble TNF receptor-II, and IL-6 are elevated in serum but, due to their short half-life and the complexity of the cytokine network, it remains to be determined whether they can be used as biomarkers in a clinical setting. IL-18 is a member of the IL-1 cytokine superfamily and plays a key role in the regulation of immunity and infl ammation [8] . Its biological eff ect is regulated at diff erent levels. IL-18 is synthesized as a larger precursor protein that requires caspase-1-mediated cleavage for activation. For IL-18 cell signaling, IL-18 binds to the IL-18 receptor (IL-18R)α with relatively low affi nity and attracts the signal transducing IL-18Rβ chain (also termed the IL-1R accessory protein-like chain) to form a functional receptor complex. In vivo, its biological activity is also dependent on secreted IL-18 binding proteins and the soluble forms of both its receptors: IL-18Rα probably by enzymatic cleavage and IL-18Rβ as an alternative splicing event. Th eir regulatory properties might be diff erent as IL-18 binding protein ameliorates collagen-induced arthritis whereas soluble IL-18Rβ aggravates it [9, 10] . Previously, Bresnihan and colleagues [11] demonstrated raised serum levels of IL-18 and its binding protein in RA patients compared to psoriatic arthritis patients, but this did not seem to correlate with response to therapy with methotrexate, whereas CRP levels did. Interestingly, IL-18 protein expression in synovial tissue did correlate with serum CRP and disease activity in infl ammatory arthritis [12] , indicating a local role in the pathophysiology of disease. A comparative study of diff erent biomarkers, either circulating or expressed in the synovial tissue, showed the utility of serum tissue inhibitor of metalloproteinases (TIMP) as predictive for a later therapeutic response to anakinra [13] . Th is study confi rmed previous fi ndings that serum IL-18 correlates poorly with disease activity and treatment response but is highly predictive for radiographic progression of the disease [13] . Th e study of Takei and colleagues [1] demonstrates that the systemic soluble IL-18Rα complex, which in vitro exhibits antagonistic activity, probably also contains a dimeric IL-18 protein and the soluble form of the IL-18Rβ chain.
Th e serum levels of this complex were signifi cantly higher in patients with RA and adult-onset Still's disease than in healthy controls and osteoarthritis and systemic lupus erythematosus patients. Moreover, treatment of RA patients with the TNF inhibitor etanercept resulted in a signifi cant improvement in serum levels of soluble IL-18Rα complex. It remains to be seen whether the soluble IL-18Rα complex can be used for the evaluation of joint damage or disease activity but even so it could be useful for the diagnosis of RA Th e soluble IL-18Rα complex as a biomarker may capture the com plexity of the infl ammatory process: the shedding of membrane IL-18Rα as a marker of enhanced proteolytic activity; the activation and release of IL-18 by the infl ammasome as a marker of innate immunity; and the alternatively spliced soluble IL-18Rβ, which is mainly expressed in the lymphoid organs and regulates IL-18-driven T-cell immunity [10] . Currently, CRP is still a useful and reliable marker for disease activity and treatment response in the clinic. However, it is recog nized that combinations of biomarkers will greatly enhance the power for diagnosis and the soluble IL-18Rα complex may be useful in this regard for RA, but longitudinal studies and crosssectional analysis are warranted.
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